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Abstract
Next generation sequencing has enabled fast and relatively inexpensive expanded carrier screening (ECS) that can inform
couples’ reproductive decisions before conception and during pregnancy. We previously showed that a couple-based
approach to ECS for autosomal recessive (AR) conditions was acceptable and feasible for both health care professionals and
the non-pregnant target population in the Netherlands. This paper describes the acceptance of this free test-offer of
preconception ECS for 50 severe conditions, the characteristics of test-offer acceptors and decliners, their views on couple-
based ECS and reasons for accepting or declining the test-offer. We used a survey that included self-rated health, intention to
accept the test-offer, barriers to test-participation and arguments for and against test-participation. Fifteen percent of the
expected target population—couples potentially planning a pregnancy—attended pre-test counselling and 90% of these
couples proceeded with testing. Test-offer acceptors and decliners differed in their reproductive characteristics (e.g. how
soon they wanted to conceive), educational level and stated barriers to test-participation. Sparing a child a life with a severe
genetic condition was the most important reason to accept ECS. The most important reason for declining was that the test-
result would not affect participants’ reproductive decisions. Our results demonstrate that previously uninformed couples of
reproductive age, albeit a selective part, were interested in and chose to have couple-based ECS. Alleviating practical
barriers, which prevented some interested couples from participating, is recommended before nationwide implementation.
Introduction
Next generation sequencing allows fast and relatively
inexpensive simultaneous testing for carrier status of many
(rare) genetic conditions called expanded carrier screening
(ECS) [1]. Deciding what to include in ECS is a complex
issue and may depend on for example the target population
or the setting in which ECS is offered. As a study by
Chokoshvili et al. demonstrates, currently available tests
vary greatly in composition of the test-panel [2] and may
consist of autosomal recessive (AR), X-linked or in some
cases even autosomal dominant conditions. ECS can inform
reproductive decisions before and during pregnancy. Cou-
ples found to be at increased risk might wish to consider
alternative reproductive options to conceive, e.g. in vitro
fertilisation and pre-implantation genetic testing (PGT),
non-carrier donor gametes or prenatal testing.
The Genetics Department of the University Medical
Centre Groningen (UMCG) in the Netherlands developed
and validated a population-based ECS test for a limited set
of 50 severe early-onset AR conditions for which no cura-
tive treatment is available. Based on the outcome of an
international expert meeting, and supported by recent
guidelines [3, 4], we developed this gene-panel to evaluate
its potential for ECS implementation within the public
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health system. Whilst in the future, this test could also be
complemented with individual carrier screening for X-
linked conditions [5, 6], here we chose to focus on AR
conditions only, and adopted a couple-based approach. If
both members of a couple are carriers for the same AR
condition—i.e. carrier-couples—then for each pregnancy
there is a risk of one in four or 25% of an affected child. The
conditions included in the test carry no known health
implications for the individuals in the couple; the only
known health implications relate to their future offspring.
Previous research among potential users demonstrated an
interest in such a test and also identified the general prac-
titioner (GP) as the preferred provider [7, 8]. With these
results in mind, we conducted a pilot implementation study
in which GPs offered this couple-based ECS to women and
their partners from the general population at no financial
cost. The main aim of this test-offer was not to encourage as
many people as possible to undergo couple-testing. We
were primarily interested in how many eligible couples
were willing to be informed in more detail about ECS by
their GP and how many of such prepared couples made a
decision to proceed with testing. This aligns with recom-
mendations from international professional societies which
describe the main aim of ECS as to facilitate informed
reproductive decision-making [3, 4]. We previously repor-
ted that the test-offer is feasible and results in informed
choice [5]. Here, we describe the initial interest in this GP-
provided couple-based ECS from the target population, the
characteristics of couple members who decide to accept and
decline the test-offer and their reasons why.
Methods
Study design and test-offer
Figure 1 outlines the different elements of our study
design and ECS test-offer. Nine GP practices in the
catchment area of the UMCG sent out letters to all women
aged 18–40 registered with their practices, inviting them
to take part in the implementation study. Women were
asked to invite their male partners to participate and
written consent was requested from both partners. As
Fig. 1 shows, all participating couples, regardless of
whether they attended pre-test counselling or proceeded
with testing, were asked to fill out two online surveys:
Survey 1 at study onset and (if they had filled out Survey
1), Survey 2 6 months afterwards. Couples who were
interested in the test-offer, could make an appointment for
pre-test counselling with the woman’s GP within
~1 month. We asked both partners to attend counselling
together, after which they could decide whether they
would like to have the screening test.
Prior to the start of the study, all GPs received training to
prepare them for the ECS pre-test counselling and the first
two counselling sessions for each GP were supervised by a
clinical genetics professional. GPs could also refer couples at
high a priori risk (e.g. consanguineous couples) and couples
needing additional pre-test counselling directly to the
Department of Clinical Genetics. Further details about the
study design and GP involvement have been reported else-
where [5]. We also launched a publicly accessible website,
www.dragerschapstest.umcg.nl, with general information
about the study and the test that also included details on how
to ask questions to the research team. For GPs, support from
a genetic counsellor from the research team was available
throughout the study. The ECS test was offered free of
charge to participating couples. If couples received a positive
couple result, reproductive options such as PGT and prenatal
testing would be covered by statutory health insurance to all
the Dutch citizens. The Medical Research Ethics Committee
(METc) of the UMC Groningen approved the study protocol
(METc 2015/384).
Recruitment and study inclusion
Figure 2 displays the recruitment and inclusion of partici-
pants in the study. Between January and December 2016,
the GPs invited 4295 women aged 18–40 to participate.
Women over 40 were excluded from this study because
ethical issues may arise due to limited access to PGT for
women older than 40 in the Netherlands. All were asked to
return the response card to indicate their eligibility and
interest in taking part. Women were eligible for participa-
tion if they had a male partner, were planning to have
children with this partner and were not pregnant. We
excluded pregnant women for two main reasons. Firstly,
this was the first time GPs were offering ECS and our initial
training focused on the least complex pre-test counselling.
Secondly, the turn-around-time of the test-result was a
maximum of 8 weeks, which limits the time for couples to
consider a potential termination of pregnancy in case of a
positive test-result. Fourteen women were not eligible for
‘other’ reasons, for example they could not conceive bio-
logically with their partner due to gender affirming treat-
ment. A test-result was considered positive only if both
partners have a class IV or V variant in the same recessive
disease gene included in the test.
Materials and measures
Data were collected via questionnaires using the Roqua
online tool for confidential clinical data collection [9]. We
asked participants (n= 190 couples) to fill in the surveys
independently from their partners. The survey design was
based on research described in [7, 8] that explored attitudes,
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intentions and reasons for and against accepting couple-
based ECS in a hypothetical scenario. The reasons for and
against accepting ECS are based on key ethical arguments
previously described in [7]. Survey 1 recorded participants’
sociodemographic characteristics, factors related to their
relationship and reproduction, their own health and their
experiences with (presumed) hereditary conditions, genetic
counselling and testing. In addition, we collected data on
their intention to participate in testing and their perceived
barriers to test-participation. After 6 months, in Survey 2,
we collected data on how participants retrospectively
viewed their decision about ECS testing and their views on
couple-based test-provision.
Test-offer acceptance and uptake rate
We distinguished test-offer acceptance (defined as attending
pre-test counselling by the woman’s GP) from actual ECS
test-uptake because the main aim of the test-offer was to
inform couples and encourage them to discuss test-
Fig. 1 Overview of test-offer and study design
Fig. 2 Flow diagram of recruitment and inclusion
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participation with the GP if they were interested, an aim
separate from the final uptake of the couple-based ECS test
itself. We calculated an additional acceptance rate based on
the estimated eligible population (couples planning a
pregnancy). Previous research showed that ~20% of women
between 18 and 40 years of age would be eligible for the
test-offer [10, 11]. In our case, we estimated the eligible
population as 859 women (or 20% of the 4295 invited
women). Thus, in this paper, we use the following three
definitions of test-offer acceptance:
(1) The proportion of women and their partners who
accepted the test-offer as part of the total number of
women who were invited (denominator n= 4295),
(2) the proportion of women and their partners who
accepted the test-offer as part of an estimated eligible
population (denominator n= 859),
(3) the proportion of women and their partners who
accepted the test-offer (n= 130) as part of the total
number of women who participated in the study
(denominator n= 190).
Lastly, the ECS test-uptake rate was calculated as the
proportion of couples who proceeded with testing after pre-
test counselling.
Variables included in the survey
Characteristics of test-offer acceptors and decliners
Sociodemographic characteristics Age was divided into
three categories in a similar way as reported by Plantinga
et al. [7]: 18-23-24-33; >33 years of age. Participants’
educational level, marital status and religiosity were clas-
sified according to the Statistics Netherlands (CBS) defini-
tions. Educational level was further summarised as: ‘basic’
(finished primary school, lower secondary school or voca-
tional training), ‘intermediate’ (finished higher level sec-
ondary school or intermediate vocational training) or ‘high’
(finished higher vocational training or university). Rela-
tionship status was classified as ‘marriage or civil partner-
ship’, ‘living together’ or ‘not living together’. Religiosity
was measured by asking whether respondents were reli-
gious (0= no, 1= yes and practising, 2= yes, but not
practising). This was dichotomised into no or yes (including
both practising and non-practising).
Relationship and reproductive characteristics Relationship
satisfaction was measured on a 10-point scale (1= very
unsatisfied, 10= very satisfied) [12, 13]. Participants were
also asked within what timeframe they were planning to
have children and whether they already had children. To be
comparable with the other relevant Dutch studies, timing to
next pregnancy was adapted from Henneman et al., who
dichotomised into <2 years (short term) and >2 years (long
term) [14]. We further categorised these into: (<0.5 years,
0.5 years-2 years, 2–5 years, >5 years, unsure)
Health status and experiences with hereditary conditions
and genetic testing We asked participants to rate their
own health on a 5-point scale (poor, moderate, good, very
good and excellent). They were also asked whether they
suffered from a chronic condition and were presented with
fourteen categories, such as respiratory conditions (e.g.
asthma), visual problems and mental health issues (yes/no).
In addition to this, we asked respondents to indicate whe-
ther they, or any of their family members or friends, suf-
fered from a (presumed) hereditary condition and/or
whether they had ever had genetic counselling and testing
themselves.
Intention, barriers and views on couple-based test-
provision
Intention (Survey 1) Intentions towards couple-based ECS
before pre-test counselling were measured with the item ‘I
intend to accept the offer of this couple-based ECS-test’ on
a 7-point scale (unlikely–likely). Intentions were classified
into ‘unlikely’ (1-2), ‘neutral’ (3-5) and ‘likely’ (6-7).
Barriers (Survey 1) We collected data about the extent to
which participants perceived the time and effort of test-
participation, having to make a GP appointment and giving
a blood sample, as barriers for taking part in this test-offer.
These four items were measured on a Likert scale from 1 to
5 (totally disagree to totally agree).
Intention (Survey 2) We asked test-decliners whether
it was a considered decision not to proceed with testing
(yes/no). If it was not, they could indicate their reasons why
(e.g. we could not come to a common decision as a couple,
it just did not happen, I had not thought about it anymore, it
was not possible to be at the GP appointment together).
Couple-based test-offer (Survey 2) Participants were also
asked to indicate their main preference as to how test-results
were disclosed. They were asked to indicate one preference
out of the following four options: 1: couple results; 2:
individual carrier results; 3: no preference; 4: not sure.
Arguments for and against accepting the couple-based
test-offer
In Survey 1, we asked participants about the reasons why they
would accept or decline ECS testing by presenting them with
seven arguments in favour and ten arguments against (listed
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in Tables 3 and 4) taking a couple-based ECS test. We asked
all participants which single argument they considered most
important in accepting and which single argument they con-
sidered most important in declining the test-offer.
Response cards
In addition, we received explanations of 70 eligible (members
of) couples who returned the response card but decided not to
take part in the study (and therefore the ECS test).
Data analysis
Given that partners within a couple might have different
views about this couple-based ECS test-offer, individual
participants were included in the analysis for all outcome
measures apart from acceptance and uptake rate. Only
respondents who filled out survey 1 were sent survey 2 and
so response rates for survey 2 were calculated based on the
number of participants who filled out survey 1. Descriptive
data are presented using mean (SD), median (IQR) or
numbers (percentages) where appropriate. To compare test
acceptors and decliners, unpaired T-tests were used for
continuous variables and χ2 tests for categorical variables.
Analyses were done using IBM SPSS version 23 (IBM
Corp., Armonk, NY, USA).
Results
Response and study inclusion
Figure 2 is a flow diagram of the study. We received 848
response cards and in total, 509 women who returned the
response card were not eligible (reasons listed in Fig. 2).
Seventy eligible women indicated that they did not want to
participate. The eligible women who were interested in
taking part (n= 269) received detailed information about
the study, were asked to invite their partner to participate
with them and to return consent forms for both of them.
After we received their written consent, 191 couples were
eventually sent Survey 1. Subsequently, one couple was
excluded because they became pregnant before filling out
survey no. 1. Thus, in total, we included 190 couples (380
participants), 358/380 (94%) participants returned Survey 1
and 227/358 (63%) participants returned Survey 2.
Test-offer acceptance and test-uptake rate
In total, 130 couples attended pre-test counselling and 117
of these couples proceeded with testing. This resulted in the
following test-offer acceptance and test-uptake rates:
(1) Test-offer acceptance was 3% (130/4295) (95% CI
3–4%) of the total invited population (i.e. women
aged between 18 and 40 registered with the
participating GPs)
(2) Test-offer acceptance was 15% (130/859) (95% CI
13-18%) of the estimated eligible population and 68%
(130/190) (95% CI 61–75%) for the participants
included in this survey study.
(3) The uptake rate of the ECS test in participants having
attended the GP-consultation was 90% (117/130)
(95% CI 84–95%).
Characteristics of test-offer acceptors and decliners
Sociodemographic, relationship and health characteristics
Table 1 displays the characteristics of test-offer acceptors
and decliners. The average age in our study sample was 29
(SD 5.5) years and 50% of participants were between 24
and 33 years old. The majority of participants had an
intermediate or higher education (93%), and 43% had
already finished higher education. Twenty-four percent
were religious and 25% were not (yet) living together. The
relationship satisfaction rate was a median of 9 out of 10
(IQR 8–9). Fifteen percent already had children (n= 55)
and sixteen percent were planning a pregnancy within
6 months. Thirty-nine percent reported at least one
chronic condition, mainly asthma, migraine or mental
health problems, but 97% described their health as good
to excellent. Thirty percent had experiences with (sup-
posedly) hereditary conditions in their family or friends,
and 13 participants (4%) had previously had genetic
counselling and testing. Most of these participants (n=
11), made an appointment with the GP to discuss couple-
based ECS.
Test-offer acceptors and decliners differed significantly
in the highest level of education achieved: test-offer
acceptors more frequently had a higher educational
level. They also less frequently had children, were more
satisfied with their relationship and were less likely to
plan a pregnancy within the next two years. Test-offer
acceptors and decliners were comparable in age,
religiosity, experiences with genetic counselling and
testing, and having chronic and presumed hereditary
conditions.
Intention, barriers and views on this couple-based
test-offer
Table 2 displays participants’ intentions, barriers to parti-
cipation and views on couple-based test-offer.
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Intention
The majority (87%) of study participants had a positive
intention towards test-participation, but test-offer acceptors
rated their intention more often as ‘likely’ compared with
test-offer decliners (93% vs. 69%). Forty-four percent of
test-offer decliners indicated that the decision to decline the
test-offer had not been a considered one, and the reasons
they most often indicated to explain why they did not attend
pre-test counselling were ‘it just had not happened’ (n= 7)
or ‘it was not possible to make a GP appointment together
with my partner’ (n= 6).
Barriers
Test-offer decliners indicated significantly more frequently
that test-participation took a lot of time and effort. In
addition, 20% of test-offer acceptors and 35% of test-offer
decliners agreed or totally agreed with the statement that
having to make a GP appointment was a barrier to their
participation.
Views on couple-based test-provision
Fifty-seven percent of test-offer acceptors and forty-eight
percent of test-offer decliners indicated that, if they had to
indicate a single preference between couple results or indi-
vidual results they would prefer to receive couple results.
Fifteen percent of test-offer acceptors and eleven percent of
decliners would prefer a test that would give them individual
carrier states. Twenty-four percent of test-offer acceptors and
twenty-seven percent of decliners had no preference and five
percent of test-offer acceptors and fourteen percent of
decliners were not sure what they preferred.
Arguments for and against accepting the couple-
based test-offer
Table 3 shows that sparing a child a life with a severe
genetic condition was considered the single most important
argument to (potentially) accept this ECS test (29.6%).
Other arguments that participants chose as most important
were that they felt they had a responsibility as future parents
to have this test (18%) and that a good result would be a
great relief (13.0%). The distribution of these arguments
was about the same for test-offer acceptors and decliners.
Examples of ‘other’ arguments participants provided in
favour of accepting ECS were curiosity, for the benefit of
science, and due to experiences with genetic conditions in
the family. Table 4 shows that for the participating couples
the most important argument against having this ECS test
was that the test-result would not influence their decision to
have children (26.5%). Again, the distribution between test-
offer acceptors and test-offer decliners was similar (25%
and 30%, respectively). Twenty-seven percent of test-offer
acceptors and eighteen percent of test-offer decliners pro-
vided additional explanations as to why they would not
want to have the ECS test, such as a worry that after a
positive test-result they would decide not to have children at
all. Some stated they did not see any reason why not to
undergo couple-based ECS.
Table 1 Sociodemographic characteristics
Sociodemographic
characteristics






Age (year) mean (SD) 29.1 (5.5) 29.4 (5.5) 28.7 (5.4)
Gender
Female 185 (51.7) 130 (49.4) 55 (57.9)
Male 173 (48.3) 129 (49.6) 44 (44.4)
Age category
18–24 69 (19.3) 46 (17.8) 23 (23.2)
24–32 180 (50.3) 134 (51.7) 46 (46.5)
>33 109 (30.4) 79 (30.5) 30 (30.3)
Religiosity
Yes 84 (23.5) 65 (25.1) 19 (19.2)
Educational level**
Basic 25 (7.0) 14 (5.4) 11 (11.1)
Intermediate 178 (49.7) 117 (45.2) 61 (61.6)




77 (21.5) 59 (20.8) 18 (18.2)
Living together 196 (54.7) 146 (56.4) 50 (50.5)
Not living together 90 (25.1) 59 (22.8) 31 (31.3)
Children*
Yes 55 (15.4) 31 (12) 24 (24.2)
Relationship satisfaction*
Median (IQR) 9 (8–9) 9 (8–9) 8 (8–9)
Timing of next pregnancy*
<0.5 year 56 (15.6) 35 (13.5) 21 (21.2)
0.5–2 year 103 (28.8) 74 (28.6) 39 (39.4)
2–5 year 126 (35.2) 102 (39.4) 24 (24.2)
≥5 year 36 (10.1) 27 (10.4) 9 (9.1)
Unsure 27 (7.5) 21 (8.1) 6 (6.1)
Self-rated health
Excellent 90 (25.1) 73 (28.2) 17 (17.2)
Very good 129 (36.0) 95 (36.7) 34 (34.3)
Good 127 (35.5) 83 (32.0) 44 (44.4)
Moderate 12 (3.4) 8 (3.1) 4 (4.0)
Poor 0 (0.0) 0 (0.0) 0 (0.0)
Do you suffer from a chronic condition?
No 218 (60.9) 162 (62.5) 56 (56.6)
Any experiences with hereditary conditions in your family or friends?
No experience 252 (70.4) 179 (69.1) 73 (73.7)
Did you have genetic testing and counselling in the past?
Yes 13 (3.6) 11 (4.2) 2 (2.0)
Test-offer acceptors and decliners were compared using T-tests for
continuous variables and χ2 tests for categorical variables. A p value of
0.05 was considered statistically significant. *p value <0.05. **p value
<0.01
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Response cards
As Fig. 2 shows, 70 women who were eligible for study
participation explained on the response card why they were
not interested in taking part. The majority cited reasons
against having couple-based ECS, rather than issues
regarding declining study participation, such as a perception
that ECS results in over-medicalization of pregnancy, health-
related issues, no perceived need to be tested (yet) and
anticipating anxiety about the impact of a positive test-result.
Table 2 Intention, barriers and views on couple-based test-provision
Intention, barriers and views on couple-based test-provision All n (%) Test-offer acceptors n (%) Test-offer decliners n (%)
Intention (survey 1) n= 352 (6 missing) n= 256 (3 missing) n= 96 (3 missing)
Intention**
Likely 306 (86.9) 240 (92.7) 66 (68.8)
Neutral 30 (10.6) 15 (5.8) 15 (15.6)
Unlikely 19 (5.4) 4 (1.5) 15 (15.6)
Intention (survey 2) (only participants who did not have ECS testing) n= 54 n= 9 n= 45
Not having the test was a ‘deliberate’ decision
Yes 33 (61.1) 8 (88.9) 25 (55.6)
No 21 (38.9) 1 (11.1) 20 (44.4)
If not, the reason for this was:
We could not come to a common decision as a couple 0 (0) 0 (0) 0 (0)
It just did not happen 7 (33.3) 0 (0) 7 (35.0)
I had not thought about it anymore 2 (9.5) 0 (0) 2 (10.0)
It was not possible to be present at the GP appointment together 6 (28.6) 0 (0) 6 (30.0)
Other, such as pregnancy 6 (28.6) 1 (100) 5 (25.0)
Barriers (survey 1) n= 348 (10 missing) n= 256 (3 missing) n= 92 (7 missing)
I think that test-participation takes a lot of time**
Totally disagree 69 (19.8) 53 (20.7) 16 (17.4)
Disagree 149 (42.8) 123 (48.0) 26 (28.3)
Agree nor disagree 99 (28.4) 65 (25.4) 34 (37.0)
Agree 28 (8.0) 15 (5.9) 13 (14.1)
Totally agree 3 (0.9%) 0 (0) 3 (3.3)
I think that test-participation takes a lot of effort**
Totally disagree 71 (20.4) 57 (22.3) 14 (15.2)
Disagree 174 (50.0) 135 (52.7) 39 (42.4)
Agree nor disagree 83 (23.9) 55 (21.5) 28 (30.4)
Agree 17 (4.9) 8 (3.1) 9 (9.8)
Totally agree 3 (0.9) 1 (0.4) 2 (2.2)
I think having to make a GP appointment before test-participation is a barrier**
Totally disagree 55 (15.8) 48 (34.4) 7 (7.6)
Disagree 126 (36.2) 98 (38.3) 28 (30.4)
Agree nor disagree 85 (24.4) 60 (23.4) 25 (27.2)
Agree 65 (18.7) 40 (15.6) 25 (27.2)
Totally agree 17 (4.9) 10 (3.9) 7 (7.6)
I think having to give a blood sample is a barrier
Totally disagree 113 (32.5) 88 (34.4) 25 (27.2)
Disagree 129 (37.0) 93 (36.3) 36 (39.1)
Agree nor disagree 62 (17.8) 45 (17.6) 17 (18.5)
Agree 33 (9.5) 22 (8.6) 11 (12.0)
Totally agree 11 (3.2) 8 (3.1) 3 (3.3)
Views on couple-based test-provision (T2) n= 221 (6 missing) n= 177 (5 missing) n= 44 (1 missing)
Preferences for disclosure of ECS results
Couple results only 122 (53.7) 101 (57.1) 21 (47.7)
Individual results 32 (14.1) 27 (15.3) 5 (11.4)
No preference 52 (22.9) 40 (22.6) 12 (27.3)
Not sure 15 (6.6) 9 (5.1) 6 (13.6)
Test-offer acceptors and decliners were, where relevant, compared using T-tests for continuous variables and χ2 tests for categorical variables. A
p value of 0.05 was considered statistically significant
**p value < 0.01
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Discussion
This paper presents the initial interest from women
18–40 years and their partners of the first offer of cost-free
couple-based ECS by trained (Dutch) GPs to couples from
the general population and identifies their characteristics,
views and barriers in terms of access and acceptance. Our
results demonstrate that ~3% of all women approached and
15% of the estimated target population attended pre-test
counselling with their GP, that is, were test-offer acceptors,
of whom 90% proceeded with the test.
A few other studies have looked at uptake for single/
few genes carrier testing in the Dutch general population.
Henneman et al. [10] reported a 25% rate of test-offer
acceptance of GP-provided cystic fibrosis (CF) carrier
screening and an acceptance rate of 10% when couples
attended educational sessions. Lakeman et al. reported a
test-offer acceptance rate of 3% in their study on ancestry-
based hemoglobinopathies and CF carrier testing by GPs
in the Netherlands [11]. Although uptake rates in our
study are similar to those from Henneman et al. [10],
differences in study design prevent direct comparison of
results. Furthermore, Gilmore et al. reported a 66%
decline rate amongst eligible women in genomic carrier
screening for reproductive purposes after being asked by
telephone to participate [15]. This suggests that more
eligible women decided to participate than in our study.
However, differences in study design, such as the mode of
invitation, eligibility criteria of having had carrier testing
previously, and the option to receive medically actionable
secondary findings, preclude direct comparison. Uptake
figures are informative because they demonstrate whether
actual uptake reflects couples’ intentions and could
highlight potential barriers in test accessibility. Although,
as we stated above, our main purpose of offering ECS in a
reproductive setting is to inform couples’ reproductive
decisions [3, 4] and maximising uptake rates is not an aim
in itself.
In line with the existing literature [11, 16], test-offer
acceptance in our study was lower than stated intentions.
Our results demonstrate that practical barriers likely
played a role for some test-offer decliners in our study, in
particular having to make an appointment with the GP
together, which was partly due to the design of our study.
It is preferable that any future nationwide large-scale test-
offer should still include pre-test counselling, because
couples prefer to discuss this type of testing with a health
professional, their GP in particular, and because this has
Table 3 The most important arguments in favour or having a couple-based ECS test





n= 96 (3 missing)
I think that my partner and I as (future) parents have a responsibility to do this test 63 (17.7) 50 (19.3) 13 (13.5)
I want to spare our child a life with a severe hereditary disease 105 (29.6) 78 (30.1) 27 (28.1)
If the test shows that we together are not carriers, this would be a great relief 46 (13.0) 33 (12.7) 13 (13.5)
I want to prevent my partner and I having to take care of a child with a severe hereditary disease 38 (10.7) 33 (12.7) 5 (5.2)
I want to know in good time if our child is at risk so as not to be confronted by having to make a
choice about a late abortion
38 (10.7) 28 (10.8) 10 (10.4)
I want to be able to prepare myself for having a child with a severe hereditary disease 36 (10.1) 23 (8.9) 13 (13.5)
I think that abortion should be prevented if possible 6 (1.7) 1 (0.4) 5 (5.2)
Other (e.g. to benefit science, previous experiences with genetic conditions in the family) 23 (6.5) 13 (5.0) 10 (10.4)
Table 4 The most important arguments against having a couple-based ECS test





n= 96 (3 missing)
I do not want to know if my partner and I are carriers 27 (7.6) 14 (5.4) 13 (13.5)
I am against selecting children by screening (such as in this test) 13 (3.7) 7 (2.7) 6 (6.3)
I am afraid that if we turn out to be carriers this will have consequences for my relationship 33 (9.3) 22 (8.5) 11 (11.5)
I am afraid that if we turn out to be carriers this will have consequences for my insurance policies 12 (3.4) 12 (4.6) 0 (0)
I am afraid that if we turn out to be carriers we will be regarded as people with a disease 7 (2.0) 7 (2.7) 0 (0)
I am afraid that if we turn out to be carriers this will be registered with the authorities 11 (2.8) 10 (3.9) 1 (1.0)
I am afraid that if we turn out to be carriers we will end up in a medical treadmill 46 (13.0) 35 (13.5) 11 (11.5)
The test-result will have no influence on my having children with my partner 94 (26.5) 65 (25.1) 29 (30.2)
A test would take away the romance of a pregnancy 19 (5.4) 12 (4.6) 7 (7.3)
By taking a test, becoming pregnant is no longer natural 6 (1.7) 5 (1.9) 1 (1.0)
Other contra arguments (e.g. I do not see any reason why not to accept the test-offer) 87 (24.5) 70 (27.0) 17 (17.7)
GP-provided couple-based expanded preconception carrier screening in the Dutch general population: who. . . 189
shown to be feasible and resulted in informed decisions
[7]. Gilmore et al. also found that logistical barriers such
as lack of time were reasons mentioned frequently for
women to decline participation in genomic carrier
screening [15]. In addition, Gilmore et al. suggest that
healthy individuals might not feel as much need to over-
come barriers to test-participation in comparison to
affected populations (such as parents of children affected
by a genetic condition), where test-participation is usually
higher [15]. Opportunities to alleviate the impact of these
barriers are available and include web consultations with
GPs, consultations outside office hours, and targeted
information materials or decision aids to increase effi-
ciency of the pre-test counselling, as well as the possibi-
lity to consult genetics professionals when necessary.
Apart from practical barriers, there are alternative rea-
sons why the uptake rates in our study may deviate from
those expected in future nationwide large-scale imple-
mentation. Firstly, the study was conducted in the northern
part of the Netherlands, an area where participation in
reproductive/prenatal genetic testing is typically lower than
other areas of the Netherlands [17]. In addition, design
related issues other than attending GP counselling with both
partners may have resulted in lower acceptance rates. Most
notable examples are the study’s consent procedure where
29% of women interested in participation did not return the
consent forms and the test-offer was conditional upon sur-
vey participation. Secondly, our test-offer was a new and
one-time offer, as ECS is not (yet) part of routine pre-
conception care. Given that not all pregnancies are planned
and most couples access health services prenatally rather
than prior to conception, offering ECS during pregnancy as
well may improve access to care. Finally, given that our test
was free of charge, we could not study to what extent co-
payment might be a barrier to test-participation. Research
indicates that whilst people are willing to pay for ECS
[7, 18], the price people are willing to pay is often lower
than the actual cost of the test itself; thus, financial barriers
might also diminish access to care, particularly for couples
with low income.
Acceptors and decliners
The majority of study participants had a positive intention
towards test-participation, and this was high even among
test-decliners (69%). Test-offer acceptors and decliners in
our study were comparable in terms of sociodemographic
characteristics, health status and experiences with chronic or
hereditary conditions. In contrast to Gilmore et al. and to
our expectations, we did not find that participants having
experiences with any kind of, self-defined (presumed) her-
editary conditions more frequently accepted testing [15]. In
our study, couples who had experiences with (presumed)
hereditary conditions, may have associated this less with
their reproductive risk of having children with the specific
severe AR conditions in this ECS test. The difference may
also partly be due to the possibility to receive medically
actionable secondary findings, as Kauffman et al., reporting
on the same study, found that participants’ main motivation
was to obtain this general health information. Most
experiences with (presumed) hereditary conditions are
likely to be adult-onset disease [19].
Test-offer acceptors more often had a higher educational
level than test-offer decliners, which was also higher than
the Dutch general population [20]. Other studies on repro-
ductive genetic counselling and testing show similar find-
ings [15, 17, 21]. Acceptors also differed from decliners
regarding their reproductive/relationship profile in this
study: they less often already had children, had a higher
relationship satisfaction, and were less likely to plan their
pregnancy in the very near future. These differences may
suggest selection bias, but unequal representation is only
problematic when access to the ECS test and information
leading to informed choice are not equally available to all
couples planning a pregnancy. Further research on the
determinants of test-offer acceptance including these
aspects, couples’ decision-making and couple dynamics,
may help to identify relevant subgroups of patients
to tailor information strategies and remove barriers to
test-participation. The intention rate for ECS testing of
participants in this study (87%) was more than double the
intention rate in our previous survey study investigating
couple-based ECS testing in a representative sample from
the general population (34%) [7]. We therefore identified a
subsection of this population who would like to make use of
couple-based ECS when it was made available to them
through the GP free of charge, but it is unlikely that the
participants’ characteristics are generalisable to all couples
of reproductive age.
Reasons to accept and decline
We asked all participants to indicate their reasons for or
against taking part in ECS, regardless of whether they chose
to accept the test-offer. The reasons test-offer acceptors and
test-offer decliners considered most important for or against
ECS did not differ much. This was unexpected, but an
explanation for these similarities might be the relatively
homogenous study sample of which most started with the
intention to accept this couple-based ECS test-offer. At the
same time, we were also interested in understanding why
not all eligible couples were interested in taking part. The
explanations on the response cards reflected a variety of
ethical, personal and practical arguments. Given that we
only had access to a small group of those eligible women
who decided not to take part in the study, more in depth
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exploration of motivations for undertaking and not under-
taking ECS in the general population could be helpful to
gain a better understanding of the desirability of offering
ECS and potential barriers preventing all eligible couples
from accessing ECS. The most important reason for parti-
cipants to accept (to spare a child a life with a severe genetic
condition) or decline testing (the test would not alter their
reproductive plans) are in line with the literature [3, 7, 22]
and align with the current aim of offering ECS testing
(enhancing couples’ reproductive choice); participants’
reasons to decline the test-offer were not based on mis-
understanding about the purpose of the test, or fears of
discrimination or stigmatisation. As second most important
reason to accept couple-based ECS, 18% of participants
considered this their responsibility as a future parent. The
perceived feeling of responsibility as a future parent to
undergo ECS, is also brought forward in the paper of Van
der Hout et al., who discuss this should be included as an
aim for a (preconception) ECS test-offer alongside repro-
ductive choice [23].
If they have to indicate a single preference after being
informed about the aims of ECS, the majority of study
participants indicated a preference for a couple-based
approach over disclosing individual results. These results
underline the findings of our previous study amongst
potential users about couples’ views on couple-based ECS
[6]. It should be noted that the response rate of survey 2 was
relatively low in comparison to that of survey 1. Most of the
drop-outs were test-offer decliners, who had a 45%
response rate compared with 70% for test-offer acceptors.
This means that the findings from survey 2 should be
viewed with caution regarding the views of test-offer
decliners. Regarding potential differences, participants with
a higher educational level were more likely to respond to
survey 2.
Given that it is the combined ‘couple-result’ which
conveys information for reproductive decision-making,
arguably, ECS couple-testing would be the new approach to
offer carrier screening for AR conditions to the general
population. This couple-based ECS test-offer could be
complemented with individual carrier screening for X-
linked conditions in the future. In this study, we focused on
couple-based ECS as a free of charge test-offer in the Dutch
public health system. We acknowledge that currently, ECS
is not yet equally available and/or affordable to all couples
planning a pregnancy. That is why, in certain contexts,
arguments for couple-based testing or reporting individual
carrier states may be different, such as for high frequency
conditions in certain populations especially when cascade
testing is reimbursed and population-based ECS is not (yet),
when using whole exome sequencing in consanguineous
populations and for ECS in a private setting.
Conclusion
This study demonstrated that at least 15% of previously
uninformed couples planning a pregnancy albeit a selective
part, were interested and accepted the offer of a free, GP-
provided couple-based ECS test. Lowering practical barriers,
as identified in this study, leading to a test-offer that is easily
and equally available to all couples planning a pregnancy
could facilitate access for those with the intention to partici-
pate. Understanding the determinants for test-uptake and the
barriers for non-participation of interested couples are
necessary for the development of health policy and can
inform future implementation of ECS in different settings.
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